2.11 USD
+0.30
16.57%
At close Apr 30, 4:00 PM EDT
Pre-market
2.07
-0.04
1.90%
1 day
16.57%
5 days
37.91%
1 month
0.48%
3 months
-35.87%
6 months
-52.90%
Year to date
-50.24%
1 year
-86.25%
5 years
-88.47%
10 years
-99.18%
 

About: Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Employees: 33

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

650% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 2

29% more funds holding

Funds holding: 31 [Q3] → 40 (+9) [Q4]

4.25% more ownership

Funds ownership: 33.62% [Q3] → 37.87% (+4.25%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

9% less capital invested

Capital invested by funds: $10.8M [Q3] → $9.82M (-$1.02M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16
658%
upside
Avg. target
$16
658%
upside
High target
$16
658%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Edward White
22% 1-year accuracy
32 / 148 met price target
658%upside
$16
Buy
Maintained
31 Mar 2025

Financial journalist opinion

Neutral
PRNewsWire
1 day ago
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
LEXINGTON, Mass. , April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m.
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
Neutral
PRNewsWire
4 weeks ago
Curis to Present at Upcoming Healthcare Conference in April
LEXINGTON, Mass. , April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation.
Curis to Present at Upcoming Healthcare Conference in April
Neutral
Seeking Alpha
1 month ago
Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President and CEO Jonathan Zung - Chief Development Officer Conference Call Participants Sean McCutcheon - Raymond James Li Watsek - Cantor Fitzgerald Ed White - H.C. Wainwright Operator Good morning, and welcome to Curis's Fourth Quarter 2024 Business Update Call.
Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
Curis Provides Fourth Quarter 2024 Business Update
FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis Provides Fourth Quarter 2024 Business Update
Neutral
PRNewsWire
1 month ago
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
LEXINGTON, Mass. , March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m.
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
Neutral
PRNewsWire
4 months ago
Curis Announces Additional Data from TakeAim Leukemia Study
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.
Curis Announces Additional Data from TakeAim Leukemia Study
Neutral
Seeking Alpha
5 months ago
Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Jonathan Zung - Chief Development Officer Conference Call Participants Ed White - H.C. Wainwright Billal Jahangiri - Truist Securities Daniel Bronder - Cantor Sean McCutcheon - Raymond James Operator Good morning, ladies and gentlemen, and welcome to the Curis Third Quarter 2024 Business Update Call.
Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
5 months ago
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.88. This compares to loss of $2.13 per share a year ago.
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
Neutral
PRNewsWire
5 months ago
Curis Provides Third Quarter 2024 Business Update
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis Provides Third Quarter 2024 Business Update
Neutral
PRNewsWire
5 months ago
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
LEXINGTON, Mass. , Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m.
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
Charts implemented using Lightweight Charts™